October 21, 2025British Journal of Ophthalmology

Systemic Rho-kinase inhibitor belumosudil for treatment of ocular graft versus host disease

View Full Paper

Ask AI

Bookmark

Authors

CGCharlyn GomezUniversity of Maryland, Baltimore FGFernando Martinez GuaschUniversity of Maryland, Baltimore VJVishal JhanjiUPMC Health System

Discussion

Member takes

Implication

Case series reports improvement in ocular symptoms in patients with chronic ocular graft versus host disease, indicating potential benefits of belumosudil treatment.

Key Points

Belumosudil treatment improved ocular symptoms in chronic ocular graft versus host disease patients, with stabilization in visual acuity.
Three out of seven patients had reduced corneal fluorescein staining after treatment of an average of 22.3 months.
Resolution of filamentary keratopathy occurred in four patients, along with improved comfort scores.
The findings suggest that belumosudil may offer clinical benefits, warranting further investigation.

Cite This Study

Gomez et al. (2025) studied this question.

synapsesocial.com/papers/68f74e597f21f73e19e5b4f3 https://doi.org/10.1136/bjo-2025-327877

View Full Paper

Ask AI

Bookmark

Implication

Case series reports improvement in ocular symptoms in patients with chronic ocular graft versus host disease, indicating potential benefits of belumosudil treatment.

Systemic Rho-kinase inhibitor belumosudil for treatment of ocular graft versus host disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Systemic Rho-kinase inhibitor belumosudil for treatment of ocular graft versus host disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider